David Caron, PharmD, is a senior CMC executive with 30 years of experience in drug development. Previously David served as VP, CMC & Pharmaceutical Development at Chiasma (NASDAQ:CHMA), a biopharmaceutical company focused on orphan diseases. At Chiasma, David set up the company’s CMC and pharmaceutical development programs and managed timelines; was responsible for the formulation and analytical development of new products, in analytical chemistry and product stability, shipment validation to point of up to commercialization, including its human, budget and technology resources; planned and executed scale-up and technical transfer of development of stage products; and planned and executed performance process qualification of a commercial product, among others. David has also held senior CMC roles at Mother’s Choice, Aposense (TASE:APOS), Cobalt Pharmaceuticals, Merck Generics, Perio Products and ABIC/Teva Pharmaceuticals (NYSE:TEVA). David earned a Doctor of Pharmacy, specializing in Pharmaceutical Technology, at the University of Pharmacy, Lyon, France.